Posted by Michael Wonder on 10 Oct 2022
scPharmaceuticals announces FDA approval of Furoscix (furosemide), the first and only self-administered, subcutaneous loop diuretic for the at home treatment of congestion in chronic heart failure
10 October 2022 - Furoscix demonstrated 99.6% bioavailability and produced similar diuresis and natriuresis compared to intravenous furosemide.
scPharmaceuticals today announced that the US FDA has approved Furoscix (furosemide), a proprietary formulation of furosemide delivered via an on body infusor for the treatment of congestion due to fluid overload in adults with New York Heart Association class II/III chronic heart failure.
